Scott Hensley

Updated March 24, 2021 at 11:03 PM ET

AstraZeneca's latest data analysis affirms effectiveness of its COVID-19 vaccine and is roughly in line with the results released Monday.

A third COVID-19 vaccine is on the way, and this one requires only one shot for immunization.

The Food and Drug Administration authorized Johnson & Johnson's vaccine for emergency use Saturday, a day after a panel of advisers to the agency voted unanimously (22-0) in its favor.

In a unanimous 22-0, a panel of advisers to the Food and Drug Administration recommended that the COVID-19 vaccine developed by Johnson & Johnson be authorized for emergency use in adults during the pandemic.

The vote in favor of the vaccine, which requires only one shot for protection, was taken to answer this question: Do the benefits of the Johnson & Johnson vaccine outweigh its risks for use in people 18 years of age and older.

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that supports its authorization for emergency use.

On Friday, a panel of advisers to the agency will meet to evaluate the vaccine and make a recommendation about whether it should be given the OK. If the agency goes on to authorize the Johnson & Johnson vaccine, it would be the third, after those made by Pfizer-BioNTech and Moderna, to become available in the U.S.

A global study of nearly 44,000 found that the COVID-19 vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease.

The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.

The biotech company Novavax says its COVID-19 vaccine is 89% effective at preventing the illness, according to an interim analysis of a large study conducted in the U.K.

The results come from a clinical trial involving more than 15,000 volunteers, of whom more than a quarter were older than 65.

The company says 62 cases of COVID-19 were seen in the study. Fifty-six occurred in the group that got placebo; six were seen in people who received the vaccine.

As the rollout of COVID-19 vaccines unfolds in the U.S., numerous questions around distribution, supply, hesitancy and efficacy persist. Experts from Harvard and the CDC will tackle these questions.

Watch an expert panel discussion on the effort to deploy against COVID-19 on Friday, Jan. 22, to be live-streamed here at 12 p.m. ET, as part of The Forum at the Harvard T.H. Chan School of Public Health.

You can email your questions to theforum@hsph.harvard.edu.

In a 20-0 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended that the COVID-19 vaccine being developed by Moderna be authorized for emergency use in adults during the pandemic.

If the agency authorizes the vaccine for emergency use, as is expected, it would become the second to be deployed in the U.S to fight the coronavirus.

The vote in favor of the vaccine was taken to answer the agency's question: Do the benefits of the Moderna vaccine outweigh its risks for use in people age 18 and older?

The Food and Drug Administration released a detailed analysis Tuesday morning of the COVID-19 vaccine from drugmaker Moderna that supports the authorization of the company's vaccine for emergency use.

The FDA's briefing document along with one from Moderna were posted two days before a group of experts will convene to advise the agency on whether to grant the vaccine emergency authorization for use, or EUA, during the pandemic.

Updated at 8:22 p.m. ET

In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic.

The vote in favor of the vaccine was taken to answer the agency's question: Do the benefits of the Pfizer-BioNTech COVID-19 vaccine outweigh its risks for use in people age 16 and older?

The agency typically follows the advice of its expert advisers.

The Food and Drug Administration released a detailed analysis Tuesday morning of the COVID-19 vaccine from Pfizer and its partner BioNTech ahead of a Thursday meeting of a group of independent experts that will advise the agency on whether to grant the vaccine an emergency use authorization.

The race to find vaccines to protect people from COVID-19 is beginning to pay off.

Clinical trials of vaccines from Moderna and a partnership of Pfizer and BioNTech have now found their experimental vaccines to be highly effective.

Facebook and Twitter took measures to screen against misinformation after President Trump put posts on both sites that falsely claimed COVID-19 is less deadly than the flu in "most populations."

Facebook took down Trump's post, saying that users are not allowed to make false claims about the severity of the pandemic. The social network says the post broke its rules against harmful misinformation.

President Trump has drawn repeated comparisons between the novel coronavirus outbreak and the flu season.

"We have a lot of people dying from the flu on top of everything else," he said Monday. "It's very bad. It looks like it could be over 50,000."

The reality so far for the current flu season is still emerging. There have been at least 23,000 deaths from flu during the 2019-2020 season, according to estimates by the Centers for Disease Control and Prevention. The upper range of the estimate for deaths is 59,000.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

At some point nearly everyone has to deal with pain.

How do Americans experience and cope with pain that makes everyday life harder? We asked in the latest NPR-IBM Watson Health Poll.

First, we wanted to know how often pain interferes with people's ability to work, go to school or engage in other activities. Overall, 18% of Americans say that's often a problem for them. Almost a quarter – 24% — say it's sometimes the case.

Do you find yourself getting ticked off more often than you used to?

If the answer is yes, you're not alone.

Some 84% of people surveyed said Americans are angrier today compared with a generation ago, according to the latest NPR-IBM Watson Health poll.

When asked about their own feelings, 42% of those polled said they were angrier in the past year than they had been further back in time.

Anger can have an effect on health.

Sniffles, sore throats and fevers seem to be all around lately.

If things get bad enough for you or a loved one to seek care, what are your expectations about treatment? Do you want a prescription for an antibiotic if symptoms suggest an infection?

If you're not feeling well or have a routine health issue, do you go ahead and get it checked out or put if off because of the cost?

And, let's say you do make an appointment and go. Afterward, do you fill the prescription you received or do financial concerns stop you?

We wondered how often people deferred or skipped care because of cost, so we asked in the latest NPR-IBM Watson Health Health Poll. The survey queried more than 3,000 households nationwide in July.

We need your help to make Shots better.

Would you be willing to take 10 or 15 minutes to complete a survey about Shots? We'd be grateful if you would.

Your opinions will help us improve Shots and make it more useful for you.

We're particularly interested in finding out what you like, what you'd like to see changed and how Shots fits in with your other sources of health news and information.

Believe it or not, Shots has been around for more than nine years.

U.S. Surgeon General Jerome Adams made a plea in April for more Americans to be prepared to administer naloxone, an opioid antidote, in case they or people close to them suffer an overdose.

"The call to action is to recognize if you're at risk," Adams told NPR's Rachel Martin. "And if you or a loved one are at risk, keep within reach, know how to use naloxone."

Surgeon, author and checklist-evangelist Atul Gawande has been picked to lead the health care venture formed by online giant Amazon, conglomerate Berkshire Hathaway and banking juggernaut JPMorgan.

It's an interesting choice.

Gawande, a general and endocrine surgeon at Brigham and Women's Hospital in Boston, is probably best known for his work writing about health care for The New Yorker and in books that include the influential Checklist Manifesto.

My mom is old-fashioned, so I got her flowers for Mother's Day. But there was no shortage of promotion for an alternative gift — a genetic test.

23andMe ran TV ads that urged people to "Celebrate Your Mom" by giving her a genetic test for Mother's Day. Better yet, take a test together, an ad suggested. Twenty percent off just for the occasion.

NPR and Kaiser Health News are undertaking a project to investigate and dissect real-life medical bills.

We expect that examining the bills will shed light on the often surprising prices for health care in the U.S.

Along the way, we're hoping to help people learn how to be more active and successful in managing the costs of their care.

When Jeff Bezos, Warren Buffett and Jamie Dimon get together to make an announcement (any kind of announcement), it's sure to grab attention.

It's not often in the midst of an antitrust fight that the public gets a look at the gamesmanship that's happening behind the scenes.

But thanks to the Huffington Post's Jonathan Cohn and Jeff Young, we got a glimpse at how health insurer Aetna is making its case to acquire rival Humana — and new insight into Aetna's decision announced Tuesday to pull out of Obamcare exchanges in 11 states.

Concussions have become part of the daily news. But how much have these brain injuries become part of daily life?

To find out, we asked people across the country about concussions in the latest NPR-Truven Health Analytics Health Poll.

The poll, conducted during the first half of March, found that nearly a quarter of people — 23 percent of those surveyed — said they had suffered a concussion at some point in their lives. Among those who said they'd had a concussion, more than three-quarters had sought medical treatment.

Republican front-runner Donald Trump released a seven-point plan to change the country's health care system that includes several familiar GOP proposals and one that puts him in agreement with, believe it or not, Democratic hopeful Bernie Sanders.

In early September, the National Institutes of Health halted a study that aimed to figure out the right blood pressure goal for people with hypertension and other risks for heart disease and stroke.

The accepted target has been to get patients' systolic pressure (the first number in the pair used to gauge blood pressure) below 140. This study tested whether lowering systolic pressure below 120 would be a better idea.

A majority of Americans say electronic cigarettes should be regulated by the Food and Drug Administration the same way the agency handles cigarettes containing tobacco, according to results from the latest NPR-Truven Health Analytics Health Poll.

Overall, 57 percent of people said the FDA should regulate e-cigarettes like tobacco products. The proportion of people in favor of regulation rose with age and education. Nearly, two-thirds of people with college degrees or graduate degrees supported regulation compared with 48 percent with high school diplomas or less.

Pages